FINWIRES · TerminalLIVE
FINWIRES

研究快讯:惠普:三月季度业绩不佳,国内外市场均面临挑战

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:惠普第三季度调整后每股运营亏损0.38美元,较第二季度的0.15美元亏损有所恶化,且低于市场预期0.34美元。受业务活动减少的影响,营收为9.32亿美元,环比下降8.4%。由于所有业务板块的利润率持续收窄,调整后EBITDA为1.78亿美元,环比下降23%。区域性不利因素众多,北美地区直接利润下降10%至2.15亿美元,主要原因是平均活跃钻机数量减少和价格压力;国际业务利润暴跌60%至1150万美元,主要原因是自2月28日起中东冲突的影响。管理层预计北美地区直接利润将在第四季度回升至2.3亿至2.4亿美元,但鉴于持续的地缘政治不确定性,对国际业务的预期范围非常宽泛,为1200万至3200万美元。惠普通过完成尤蒂卡广场的出售,税后收益超过 1 亿美元,并提前偿还了 4 亿美元的债务,从而显著增强了其资产负债表,同时向股东返还了 2500 万美元,并专注于 2027 年到期的 3.5 亿美元债券。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661